These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 17603981)

  • 1. Glucotoxicity in peritoneal dialysis--solutions for the solution!
    Holmes CJ
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):269-78. PubMed ID: 17603981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatible peritoneal dialysis solutions: do we have one?
    Chaudhary K; Khanna R
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):723-32. PubMed ID: 20093342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
    Higuchi C; Nishimura H; Sanaka T
    Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
    Haag-Weber M
    Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution.
    Kim YL; Cho JH; Choi JY; Kim CD; Park SH
    J Ren Nutr; 2013 May; 23(3):218-22. PubMed ID: 23510669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solutes transport characteristics in peritoneal dialysis: variations in glucose and insulin serum levels.
    da Silva DR; Figueiredo AE; Antonello IC; Poli de Figueiredo CE; d'Avila DO
    Ren Fail; 2008; 30(2):175-9. PubMed ID: 18300117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
    Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
    Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protecting the peritoneal membrane in dialyzed patients.
    Grzegorzewska AE
    Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in non-diabetic patients with end-stage renal disease.
    Jiang N; Qian J; Lin A; Lindholm B; Axelsson J; Yao Q
    Blood Purif; 2008; 26(5):423-8. PubMed ID: 18776721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.
    de Lima SM; Otoni A; Sabino Ade P; Dusse LM; Gomes KB; Pinto SW; Marinho MA; Rios DR
    Clin Chim Acta; 2013 Jun; 421():46-50. PubMed ID: 23466603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
    Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
    Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
    Perl J; Nessim SJ; Bargman JM
    Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of glucose in peritoneal dialysis: saint or sinner?
    Sitter T; Sauter M
    Perit Dial Int; 2005; 25(5):415-25. PubMed ID: 16178471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimal use of peritoneal dialysis fluids in type 2 diabetes mellitus patients].
    Ryckelynck JP; Allard C; Cousin M; Hurault de Ligny B; El Haggan W; Lobbedez T
    Nephrol Ther; 2006 Jan; 2 Suppl 1():S82-5. PubMed ID: 17378147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern.
    Chung SH; Heimbürger O; Lindholm B
    Semin Dial; 2008; 21(1):7-10. PubMed ID: 18251948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDPs and AGEs: impact on cardiovascular toxicity in dialysis patients.
    Himmele R; Sawin DA; Diaz-Buxo JA
    Adv Perit Dial; 2011; 27():22-6. PubMed ID: 22073823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alternative dialysis solutions in continuous ambulatory peritoneal dialysis].
    Olszowska A; Baczyński D
    Pol Merkur Lekarski; 1998 Nov; 5(29):307-9. PubMed ID: 10101509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
    Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
    Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.